Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced the filing of PCT/US2026/45955, expanding the Company’s growing intellectual property portfolio around its novel splicing-modulating payload, PH1 and PH1-based ADCs.